There is a low but not negligible rate of IBD occurrence when administering IL-17 inhibitors to axSpA patients and a high suspicion should be retained towards pre-existing or current gastrointestinal symptomatology in these patients. This evidence concerns the gene IL17A and inflammatory bowel disease.